Last reviewed · How we verify
HB0017
At a glance
| Generic name | HB0017 |
|---|---|
| Also known as | HB0017 dosing regimens, recombinant humanized IgG1 monoclonal antibody |
| Sponsor | Huabo Biopharm Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Study of HB0017 in Psoriasis Patients (PHASE2)
- Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis (PHASE3)
- A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis (PHASE2)
- A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis (PHASE1)
- A Study of Injection HB0017 in Adult Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HB0017 CI brief — competitive landscape report
- HB0017 updates RSS · CI watch RSS
- Huabo Biopharm Co., Ltd. portfolio CI